Publication

Targeting the Progesterone Receptor in Breast Cancer: Mind the Short Form!

Cathrin Brisken, Carlos Henrique Venturi Ronchi
2023
Journal Articles

Abstract

The presurgical window of opportunity trial (WOT) MIPRA provides evidence that neoadjuvant treatment with the prog-esterone receptor (PR) antagonist mifepristone (RU486) may benefit patients with estrogen receptor-positive (ER+) breast cancer characterized by a high ratio of PR-A versus PR-B iso-form (>1.5), suggesting that PR may be targeted in a subset of patients. See related article by Elia et al., p. 866

Official source

https://infoscience.epfl.ch/entities/publication/91c62664-329a-4f7d-870c-9a263b3a04d9

About this result

This page is automatically generated and may contain information that is not correct, complete, up-to-date, or relevant to your search query. The same applies to every other page on this website. Please make sure to verify the information with EPFL's official sources.

Graph Chat

Chat with Graph Search

Ask any question about EPFL courses, lectures, exercises, research, news, etc. or try the example questions below.

DISCLAIMER: The Graph Chatbot is not programmed to provide explicit or categorical answers to your questions. Rather, it transforms your questions into API requests that are distributed across the various IT services officially administered by EPFL. Its purpose is solely to collect and recommend relevant references to content that you can explore to help you answer your questions.

Targeting the Progesterone Receptor in Breast Cancer: Mind the Short Form!

Chat with Graph Search

Androgen Receptor Signaling in in vivo models of Estrogen Receptor-positive Breast Cancer and Normal Breast Epithelium

Technosignatures Longevity and Lindy's Law

Thermal Conditions in Indoor Environments: Exploring the Reasoning behind Standard-Based Recommendations